Bottom line
Is PUMTX a good fund? The bottom line
PUMTX is the Class P2 share class of PACE Small/Medium Co Growth Equity Investments, a managed large growth mutual fund from Pace Select Advisors.
It charges 0.69% — about $69 a year on every $10,000 invested, cheaper than 68% of large growth funds we track.
With $258 million in net assets and 316 holdings, its largest position is State Street Global Advisors (5.0%) and the top 10 make up 15.7% of the portfolio.
What stands out
- Broadly diversified (316 holdings)
- No front-end sales load
Updated Nov 19, 2026
What PUMTX invests in
Capital appreciation.
"Principal investments The fund invests primarily in stocks of ""emerging growth"" companies that are believed to have potential for high future earnings growth relative to the overall market. Under normal circumstances, the fund invests at least 80% of its net assets (plus the amount of any borrowing for investment purposes) in equity securities issued by small/medium capitalization companies. Small/medium capitalization companies means companies with a total market capitalization within the market capitalization range of the companies in the Russell 2500 ? Growth Index at the time of purchase. Dividend income is an incidental consideration in the investment advisors' selection of stocks for the fund. The fund may from time to time invest a significant portion of its assets in the stocks of companies in various economic sectors, such as technology. The fund may invest, to a limited…
From the fund's prospectus (filed Nov 25, 2025).
What PUMTX costs
On a $10,000 investment, PUMTX's 0.69% expense ratio costs about $69 a year. The prospectus estimates $1,314 in total costs over 10 years (assuming 5% annual returns). The median large growth fund charges 0.87%.
PUMTX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | State Street Global Advisors | 4.98% |
| 2 | Dave Inc | 1.38% |
| 3 | Five Below Inc | 1.34% |
| 4 | Rush Street Interactive Inc | 1.29% |
| 5 | Travere Therapeutics Inc | 1.24% |
| 6 | ATI Inc | 1.18% |
| 7 | Halozyme Therapeutics Inc | 1.15% |
| 8 | Medpace Holdings Inc | 1.07% |
| 9 | Lumentum Holdings Inc | 1.05% |
| 10 | Argan Inc | 1.05% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 15.7% of the fund. See all top 25 holdings and asset mix →